Malijan Greco Mark B, Suzuki Shuichi, Sayo Ana Ria, Villanueva Annavi Marie, Agrupis Kristal An, Ortal-Cruz Abigail, Salazar Mary Ann, Evangelista Jan Wendzl, Solante Rontgene, Go Grace Devota, Saludar Naomi Ruth, Miranda Dinarazad, Dimapilis Alexis, Ariyoshi Koya, Smith Chris
San Lazaro Hospital - Nagasaki University Collaborative Research Office, San Lazaro Hospital, Quiricada Street, Sta. Cruz, 1003, Manila, Philippines.
School of Tropical Medicine and Global Health, Nagasaki University, Sakamoto, Nagasaki, 852-8102, Japan.
Trop Med Health. 2025 Jun 16;53(1):81. doi: 10.1186/s41182-025-00767-9.
SARS-CoV-2 seroepidemiological studies, which have been used to describe population-level immunity, are limited in the Philippines, despite the protracted course of the epidemic in the country. We follow-up on our previous work and aimed to estimate SARS-CoV-2 seroprevalence and infection rate among outpatient clinic attendees in Metro Manila, a year after the implementation of the national COVID-19 vaccination program.
We conducted four repeated cross-sectional surveys at the outpatient department of San Lazaro Hospital between March 2022 and January 2023. We performed χ test and analysis of variance to assess the differences in characteristics across different data collection periods.
A total of 765 participants were enrolled, ranging from 170 to 200 per period. Participant demographic, socioeconomic, and medical history were comparable across all data collection periods. Between March and October 2022, the proportion of participants who received a vaccine or booster dose significantly increased, from 77.9% to 90%. Seroprevalence across all data collection periods was consistently high, ranging from 97.8% to 99.5%. However, the geometric mean concentration of antibodies was highest in the data collection period following the Omicron-dominant wave. Infection rates were comparably low (< 10%) across periods, except for a peak at 16.7% in September to October 2022, which followed the rise in reported cases in Metro Manila.
Population-level seroprevalence among clinic attendees in Manila was consistently high a year after implementation of the national COVID-19 vaccination program, but analyses of antibody concentrations showed potential waning within a 3-month period.
尽管菲律宾疫情持续时间较长，但用于描述人群免疫力水平的新冠病毒血清流行病学研究却很有限。我们对之前的工作进行跟进，旨在评估在国家新冠疫苗接种计划实施一年后，马尼拉大都会门诊就诊者中的新冠病毒血清阳性率和感染率。
2022年3月至2023年1月期间，我们在圣拉萨罗医院门诊部进行了四次重复横断面调查。我们进行了χ检验和方差分析，以评估不同数据收集时期特征的差异。
共纳入765名参与者，每个时期170至200人。在所有数据收集时期，参与者的人口统计学、社会经济和病史特征具有可比性。2022年3月至10月期间，接种疫苗或加强针的参与者比例显著增加，从77.9%增至90%。所有数据收集时期的血清阳性率一直很高，在97.8%至99.5%之间。然而，抗体几何平均浓度在以奥密克戎为主的疫情波之后的数据收集时期最高。各时期的感染率相对较低（<10%），但在2022年9月至10月出现了16.7%的峰值，这与马尼拉大都会报告病例的增加相一致。
在国家新冠疫苗接种计划实施一年后，马尼拉门诊就诊者的人群血清阳性率一直很高，但抗体浓度分析显示在3个月内可能出现下降。
